These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 25803193)
1. PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53. Sobhani M; Abdi J; Manujendra SN; Chen C; Chang H Cancer Biol Ther; 2015; 16(5):799-806. PubMed ID: 25803193 [TBL] [Abstract][Full Text] [Related]
2. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Saha MN; Jiang H; Yang Y; Reece D; Chang H Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633 [TBL] [Abstract][Full Text] [Related]
3. PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK. Lu T; Zou Y; Xu G; Potter JA; Taylor GL; Duan Q; Yang Q; Xiong H; Qiu H; Ye D; Zhang P; Yu S; Yuan X; Zhu F; Wang Y; Xiong H Oncotarget; 2016 Dec; 7(50):83017-83030. PubMed ID: 27806324 [TBL] [Abstract][Full Text] [Related]
4. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells. Yoshikawa N; Kajiyama H; Nakamura K; Utsumi F; Niimi K; Mitsui H; Sekiya R; Suzuki S; Shibata K; Callen D; Kikkawa F Oncol Rep; 2016 May; 35(5):2543-52. PubMed ID: 26986846 [TBL] [Abstract][Full Text] [Related]
5. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53. Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002 [TBL] [Abstract][Full Text] [Related]
6. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status. Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246 [TBL] [Abstract][Full Text] [Related]
11. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079 [TBL] [Abstract][Full Text] [Related]
13. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia. Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945 [TBL] [Abstract][Full Text] [Related]
14. Bortezomib and Waldenstrom's macroglobulinemia. Pascal L; Gay J; Willekens C; Wemeau M; Balkaran S; Robu D; Roccaro A; Morel P; Ghobrial I; Leleu X Expert Opin Pharmacother; 2009 Apr; 10(5):909-16. PubMed ID: 19351237 [TBL] [Abstract][Full Text] [Related]
15. Prima-1 and APR-246 in Cancer Therapy. Zatloukalová P; Galoczová M; Vojtěšek B Klin Onkol; 2018; 31(Suppl 2):71-76. PubMed ID: 31023027 [TBL] [Abstract][Full Text] [Related]
16. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220 [TBL] [Abstract][Full Text] [Related]